Cargando…
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
OBJECTIVES: To evaluate the risk of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with tofacitinib. METHODS: Phase II, III and long-term extension clinical trial data (April 2013 data-cut) from the tofacitinib RA programme were reviewed. OIs defined a priori inclu...
Autores principales: | Winthrop, K L, Park, S-H, Gul, A, Cardiel, M H, Gomez-Reino, J J, Tanaka, Y, Kwok, K, Lukic, T, Mortensen, E, Ponce de Leon, D, Riese, R, Valdez, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893093/ https://www.ncbi.nlm.nih.gov/pubmed/26318385 http://dx.doi.org/10.1136/annrheumdis-2015-207319 |
Ejemplares similares
-
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2014) -
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
por: Winthrop, Kevin L, et al.
Publicado: (2016) -
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
por: Cohen, Stanley B, et al.
Publicado: (2017) -
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
por: Curtis, Jeffrey R, et al.
Publicado: (2016) -
Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment
por: Winthrop, Kevin L., et al.
Publicado: (2021)